Sign In
Buy ICU
$3.28
-0.250 (-7.08%)
At Close: Jun 03, 2026
FDA Identifies ICU Medical's Plum Duo Recall as Serious Type
10:56am, Monday, 01'st Sep 2025
ICUI faces an FDA recall of its Plum Duo Infusion System over software flaws, though devices remain in use, pending fixes.
ICU Medical to Participate in Upcoming Investor Conferences
08:30am, Thursday, 21'st Aug 2025
SAN CLEMENTE, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- ICU Medical (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced its participation i
SeaStar Medical Reports Second Quarter 2025 Financial Results and Provides Business Updates
04:05pm, Wednesday, 13'th Aug 2025
Business highlights include: Adult NEUTRALIZE-AKI trial enrolls 31 new patients, now over 60% enrolled Three new top-rated children's hospitals adopt QUELIMMUNE therapy for ultra-rare pediatric Acute
ICU Medical Announces Second Quarter 2025 Results and Updates its Fiscal Year 2025 Guidance
04:05pm, Thursday, 07'th Aug 2025
SAN CLEMENTE, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial res
SeaStar Medical to Report Second Quarter Financial Results on August 13, 2025
10:00am, Thursday, 07'th Aug 2025
DENVER, Aug. 07, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing
Trial now over 60% enrolled with 125 of 200 anticipated patients Recent new site activation brings total clinical trial sites to 16 Interim analysis of first 100 patients remains on track for 3Q 2025
ICU Medical Announces Time of Second Quarter 2025 Earnings Conference Call
08:30am, Thursday, 24'th Jul 2025
SAN CLEMENTE, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of
DENVER, July 22, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company, announced today positive preliminary results from the SAVE Surveilla
SeaStar Medical Grows Customer Base and Expands QUELIMMUNE Surveillance Registry
08:45am, Wednesday, 16'th Jul 2025
Highest Rated Children's Medical Centers Now Employ QUELIMMUNE for Ultra-Rare Cases of Pediatric AKI HDE Surveillance Registry Data Captures Key Metrics for Future Analysis of QUELIMMUNE Performan
SeaStar Medical Announces $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
03:29pm, Thursday, 10'th Jul 2025
DENVER, July 10, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing
SeaStar Medical Expands QUELIMMUNE Adoption for Critically Ill Pediatric Patients with Acute Kidney Injury (AKI)
08:05am, Tuesday, 08'th Jul 2025
Nationally Recognized Texas Children's Hospital Adds First-In-Class Therapy as a Potential Life-Saving Treatment in Ultra-Rare Cases of Pediatric AKI Nationally Recognized Texas Children's Hospital Ad
SeaStar Medical Announces Positive Nasdaq Listing Determination
04:25pm, Wednesday, 02'nd Jul 2025
DENVER, July 02, 2025 (GLOBE NEWSWIRE) -- Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ f
SeaStar Medical Reports Update on Nasdaq Listing Status
08:05am, Wednesday, 25'th Jun 2025
DENVER, June 25, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing
SeaStar Medical Announces Two Feature Stories on QUELIMMUNE Adoption and Patient Testimonial of Life-Saving Therapy
09:05am, Tuesday, 24'th Jun 2025
Cincinnati Children's Hospital Medical Center Discusses QUELIMMUNE Therapy Adoption A Father and Patient Describe Their Real-Life Experience with the QUELIMMUNE Therapy DENVER, June 24, 2025 (GLOBE NE
SeaStar Medical Announces Pricing of Up to $8 Million Public Offering
12:10pm, Friday, 20'th Jun 2025
$4 million upfront with up to an additional $4 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants $4 million upfront with up to an additional $4 million of
